Company profile
TScan Therapeutics, Inc.
NASDAQ: TCRX · Healthcare · Biotechnology
#627 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
39DFH 35DQ 40GM 46SS 48
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), workforce scale · ↓ growth stability, listing tenure
Methodology →Revenue TTM
$9.1M
Rev growth YoY (TTM)
+106.7%
Net income (FY)
-$129.8M
Employees
139
as of 2026-08-19
Market cap
$50.4M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$10.3M$10.3M2025
Net income-$129.8M-$129.8M2025
Operating income-$135.8M-$135.8M2025
Total assets$228.8M$228.8M2025
Liabilities$105.7M$105.7M2025
Equity$123.1M$123.1M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Reportable100%
By geography
Not disclosed.
The read
What is TScan Therapeutics, Inc.’s revenue?
TScan Therapeutics, Inc. booked $10.3M in FY2025 revenue, growing 267% year over year — faster than 91% of Healthcare companies we track, at a -1256.8% net margin.
Peers · Healthcare
PrimeMD Inc——HealthWarehouse.com, Inc.——XOMA Royalty Corp.75B+Alpha Cognition Inc39DKhiron Life Sciences Corp.——Zenas BioPharma, Inc.33DNeighbors
Middlesex →Key facts
CEOGavin MacBeath
SectorHealthcare
IndustryBiotechnology
HeadquartersWaltham, MA
ExchangeNASDAQ: TCRX
Employees139
IPO date2021-07-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.